Merck/Schering-Plough Pharmaceuticals received FDA approval for Zetia for use, along with diet, in combination with fenofibrate for the reduction of elevated total cholesterol and LDL “bad” cholesterol in patients with mixed hyperlipidemia, when diet alone is not enough. Zetia is the first in a class of cholesterol-lowering agents that inhibits the intestinal absorption of cholesterol. Fenofibrate is commonly used along with diet to treat hyperlipidemia and has proven efficacy i...